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Cyclophosphamide as a ﬁrst-line therapy in LGL leukemia
Leukemia (2014) 28, 1134–1136; doi:10.1038/leu.2013.359
Large granular lymphocyte (LGL) leukemia is a T or NK clonal
disorder characterized by the tissue invasion of marrow, spleen
and liver. Clinical presentation is dominated by recurrent
infections associated with neutropenia, anemia, splenomegaly
and autoimmune diseases, particularly rheumatoid arthritis.1–4
Recently, STAT3 and STAT5 mutations have been detected in
T-LGL and in NK-LGL leukemias.5–8 These somatic mutations,
coupled to other intrinsic and extrinsic mechanisms, are likely to
induce constitutive activation of the JAK/STAT pathway thus
contributing to maintenance of leukemic LGL survival.9 These
ﬁndings strongly suggest a common speciﬁc pathogenic pattern
in T-LGL and NK-LGL leukemias and provide justiﬁcation for
consideration of the same treatment options. Indications for
treatment are severe or symptomatic neutropenia, symptomatic
or transfusion-dependent anemia or associated autoimmune
diseases requiring therapy. There is no standard treatment
for patients with LGL leukemia. All the largest series published in
the literature (collecting data on more than 40 patients)
are retrospective. Data are very heterogeneous and treatment
outcome per single agent is available for very few patients.
Immunosuppressive therapy remains the foundation of treatment
including single agents that is, methotrexate, oral cyclophos-
phamide or cyclosporine. On the basis of an initial study showing
very good overall response rate (ORR) using methotrexate,
this drug has remained the most recommended option in LGL
leukemia.10 Oral low dose cyclophosphamide was ﬁrst used in
pure red cell aplasia associated with LGL leukemia.11,12 In a French
series, cyclophosphamide was shown to be also efﬁcient in
neutropenic patients and for those who failed methotrexate.13
Those results suggested that cyclophosphamide used as ﬁrst-line
therapy could be an interesting alternative to methotrexate.
In this letter, we describe the encouraging results of cyclophos-
phamide used in a series of 45 previously untreated LGL leukemia
patients. Patients suffering from LGL leukemia and treated with
cyclophosphamide as ﬁrst-line therapy were included in this
retrospective study. Patients were screened from the Italian,
French and USA Penn State registries. Patients gave their informed
consent for data collection. The diagnosis of LGL leukemia was
based on a chronic LGL peripheral blood expansion (40.5 109/l),
usually lasting for more than 6 months. Criteria for T-LGL leukemia
included expression of LGL surface markers compatible with a
typical T-cell (commonly abþ or gdþ /CD3þ /CD8þ /
CD57þ and/or CD16þ ) phenotype associated with clonal
rearrangement of TCRg gene using PCR or clonal Vb expression
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using ﬂow cytometry. Criteria for NK-LGL lymphocytosis/chronic
NK-LGL leukemia included expression of LGL surface markers
compatible with a NK-cell (commonly CD3 /CD8þ /CD16þ
and/or CD56þ ) phenotype with more than 0.75 109/l circula-
ting cells.14,15 Response to treatment was determined periodically
on blood cell count and only best response was taken into
account. Hematological complete response (CR) was deﬁned by a
normal blood count (hemoglobin (Hb)412g/dl, platelets
4150 109/l, absolute neutrophil count (ANC)41.5 109/l and
lymphocytosiso4 109/l) and LGL peripheral count in a normal
range (o0.3 109/l). Molecular CR was based on hematological
CR associated with a negative PCR analysis for CD3þ cases.
Hematologic partial response was deﬁned as an improvement in
blood count speciﬁed as follows: ANC increasing more than 50%
and reaching more than 0.5 but less than 1.5 109/l; Hb level
increasing more than 2 g/dl and transfusion independent
without reaching 12g/dl level. Treatment failure was deﬁned as a
progressive disease (worsening of cytopenia or organomegaly) or a
stable disease (none of the later given criteria met). Some patients
received cyclophosphamide because of symptoms not related to
cytopenia. For those patients, response criteria included clinical
symptom resolution. Patients who received prednisone, granulocyte
colony-stimulating factor or erythropoiesis-stimulating agent before
or at the same time of cyclophosphamide were included in this
retrospective study. For the descriptive analysis, qualitative
variables were described using numbers and percentage, whereas
medians and extremes were used to describe quantitative
analyses. Qualitative variables were compared using w2 or
Fisher’s test.
A total of 45 patients treated with cyclophosphamide as a ﬁrst-
line therapy for LGL leukemia from 1989 to 2012 were retro-
spectively included in this series. Clinical characteristics are
described in Table 1. Starting doses were as follows: 100mg/day
(n¼ 36), 50 to 75mg/day (n¼ 8) taken orally and 1 g IV/month
(n¼ 1). Median time from diagnosis to treatment was 3 months
(range, 0–55). Treatment was initiated because of severe isolated
neutropenia (n¼ 16, 36%), neutropenia and anemia (n¼ 2, 4%),
transfusion-dependent anemia (n¼ 15, 33%) and thrombocyto-
penia (n¼ 5, 11% including three cases of idiopathic thrombo-
penic purpura). Seven non-cytopenic patients (15%) were treated
for disease-associated LGL leukemia: neuropathy (n¼ 3), vasculitis
(n¼ 1) and constitutive symptoms (n¼ 3). ORR was 71% (32/45):
there were 21 CR (47%) including three molecular responses
(mCR) and 11 (24%) partial responses. ORR was 72% versus 68%
for T-LGL and NK-LGL subtype, and 72% versus 67% for
neutropenic and anemic patients, respectively (P¼ not signiﬁ-
cant). Patients treated for symptoms related to LGL leukemia had
a 94% ORR (6/7). Eighteen patients (40%) were initially co-treated
with prednisone and no signiﬁcant impact was found for the
response to cyclophosphamide (P¼ 0.31). As well as, concomitant
granulocyte colony-stimulating factor administration with cyclo-
phosphamide did not inﬂuence the time to response and the ORR.
The median time to reach best response was 4 months (range 0.8–21)
and patients were treated for a median time of 6.4 months
(range 0.5–33). Evidence of clinico-biological improvement was
systematically observed within the 4 months following treatment
initiation. Therefore, we assume that cyclophosphamide should be
given for at least 4 months before changing drug regimen. Median
treatment duration was 8.5 months (range 3.4–33) for responders,
except one patient who received several courses of cyclopho-
sphamide for 7 years. With a median time follow-up of 35 months
(range 3.8–277), four out of the 32 responders relapsed (13%): one
of these patients responded again to a short course of cyclophos-
phamide and was maintained subsequently on cyclosporine decided
thereafter. The three others were switched to either methotrexate or
cyclosporine. Eight patients experienced grade 1–2 toxicities (18%).
Only three patients (7%) stopped treatment: one because of
worsened anemia and two because of febrile neutropenia
not obviously related to hematological toxicity. One patient
experienced temporary worsening of anemia without stopping
therapy.
We previously mentioned that cyclophosphamide induces a
very good ORR in LGL leukemia in de novo or relapsing patients.14
The ORR of 71% described in our series conﬁrmed and
emphasized what has been reported in the literature with a
total of 25 responders out of 38 patients treated as ﬁrst line with
cyclophosphamide (66% ORR) (Table 2).11–13,17,18 We show that
cyclophosphamide compares favorably to methotrexate given as a
ﬁrst-line therapy. In 1993, Loughran et al.10 reported a 60% ORR in
a prospective series of 10 patients receiving methotrexate at a
weekly dose of 10mg/m2. These results were less encouraging in
two larger series. One comes from the prospective ECOG study
showing a 37% ORR in 56 patients and the other is retrospective
from the French registry and reported a 44% ORR in 36
patients.13,19 Furthermore, molecular response is rarely obtained
and the incidence of relapse following methotrexate is, at least in
Table 1. Patients characteristics, n¼ 45
Median age 60 (24–90)




Median lymphocytes (109/l) 5.1 (0.5–26.8)
Median LGL (n¼ 34)a (109/l) 3.34 (0.5–25.2)
LGL44 109/l 21/34 (62%)
ANCo0.5 109/l 11/45 (24%)
Hbo11 g/dl 24/45 (53%)
Hbo8 g/dl 7/45 (16%)
Plateletso100 109/l 10/45 (22%)
LGL marrow infiltration (n¼ 40)b 29/40 (73%)




STAT3 mutation 7/20 (35%)




Abbreviations: ANC, absolute neutrophil count; F, female; Hb, hemoglobin;
LGL, large granular lymphocyte; M, male. aMedian LGL count was available
for 34 patients. bBone marrow infiltration status was only available for
40 patients, assessed on bone marrow aspirate or bone marrow biopsy
using the Morice WG criteria (diffuse interstitial pattern with small clusters
of CD8þ , TIA-1þ and granzyme Bþ cells).16 cPRCA, pure red cell aplasia;
AIHA, autoimmune hemolytic anemia; ITP, idiopathic thrombopenic
purpura. dOne patient had also Crest syndrome.
Table 2. Summary of results for cyclophosphamide used as a first-line






16 10 (63%) 6 Dhodapkar17
5 4/5 (80%) 4 Go11
8 6/8 (75%) 2 Fujishima12
4 3/4 (75%) 2 Bareau13
5 2/5 (40%) Unknown Mohan18
45 32/45 (71%) 21 Our series
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French experience, estimated at 67%.13 Our series demonstrates
that cyclophosphamide used as ﬁrst-line therapy is effective in
T/NK-LGL leukemia, in both neutropenic and anemic patients.
ORR and response duration seem encouraging. We recommend
only 9–12 months of treatment. It seems sufﬁcient to induce
durable remissions and to avoid the complication of myelodys-
plastic syndromes/acute myeloid leukemia, which although rare is
dependent on cumulative dose and length of exposure. For
responding patients, tapering dose to 50mg per day would be a
reasonable option. Although recognizing the limits of a retrospective
study, we suggest that cyclophosphamide could be an interesting
alternative to methotrexate as ﬁrst-line therapy in LGL leukemia.
A prospective study comparing cyclophosphamide to methotrexate
as ﬁrst-line therapy is currently ongoing in France.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
We thank all clinicians for providing patient data to US, Italian and French LGL
Leukemia registry. This work was supported in part by the National Institutes of
Health grants CA094872, Associazione Italiana per la Ricerca sul Cancro (AIRC),
Cariparo, Cariverona and ADHO (association pour le de´veloppement de l’he´mato-
logie-Oncologie).
AUTHOR CONTRIBUTIONS
AM and TL designed the study and performed statistical analysis. AM, ZH, LP,
BB, OT, AA, KB, RH TPL, RZ, GS and TL were responsible for data collection,
data analysis, data interpretation, manuscript preparation, writing and
completion and ﬁnal approval of manuscript. MR and TF participated in
biological analysis. All authors approved the ﬁnal version of the manuscript and
the submission.
A Moignet1, Z Hasanali2, R Zambello3, L Pavan3, B Bareau4,
O Tournilhac5, M Roussel6, T Fest6,8, A Awwad2, K Baab2,
G Semenzato3, R Houot1,7,8, TP Loughran Jr2 and T Lamy1,7,8
1Clinical Hematology Department-Rennes University Hospital,
Rennes, France;
2Penn State Hershey Cancer Institute, Pennsylvania State College of
Medicine, Hershey, PA, USA;
3Padua University School of Medicine, Department of Medicine,
Hematology & Clinical Immunology Branch, Padua, Italy;
4Clinique de Cesson Se´vigne´-Rennes, Rennes, France;
5Clinical Hematology Department, Hoˆpital Estaing,
Clermont-Ferrand, France;
6Hematology-Immunology and cell Therapy Department, Rennes
University Hospital, Rennes, France;
7INSERM, CIC 0203, France and
8Rennes 1 University, Rennes, France
E-mail: thierry.lamy@univ-rennes1.fr
REFERENCES
1 Loughran Jr TP. Clonal diseases of large granular lymphocytes. Blood 1993; 82:
1–14.
2 Loughran Jr TP, Kadin ME, Starkebaum G, Abkowitz JL, Clark EA, Disteche C et al.
Leukemia of large granular lymphocytes: association with clonal chromosomal
abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic
anemia. Ann Intern Med 1985; 102: 169–175.
3 Sokol L, Loughran Jr TP. Large granular lymphocyte leukemia. Oncologist 2006; 11:
263–273.
4 Lamy T, Loughran Jr TP. Clinical features of large granular lymphocyte leukemia.
Semin Hematol 2003; 40: 185–195.
5 Jerez A, Clemente MJ, Makishima H, van Adrichem AJ, Kuusanma¨ki H, Andersson EI
et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative
disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012;
120: 3048–3057.
6 Koskela HL, Eldfors S, Ellonen P, Koskela H, LeBlanc F, Peng NgK et al. Somatic STAT3
mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366: 1905–1913.
7 Fasan A, Kern W, Grossmann V, Haferlach C, Haferlach T, Schnittger S.
STAT3 mutations are highly speciﬁc for large granular lymphocytic leukemia.
Leukemia 2012; 27: 1598–1600.
8 Rajala HL, Eldfors S, Kuusanmaki H, van Adrichem AJ, Olson T, Lagstro¨m S et al.
Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia.
Blood 2013; 121: 4541–4550.
9 Teramo A, Gattazzo C, Passeri F, Lico A, Tasca G, Cabrelle A et al. Intrinsic and
extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly
activated in T-type large granular lymphocyte leukemia. Blood 2013; 121: 3843–3854.
10 Loughran Jr TP, Kidd PG, Starkebaum G. Treatment of large granular lymphocyte
leukemia with oral low-dose methotrexate. Blood 1994; 84: 2164–2170.
11 Go RS, Li CY, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated
with lymphoproliferative disease of granular T lymphocytes. Blood 2001; 98: 483–485.
12 Fujishima N, Sawada K, Hirokawa M, Oshimi K, Sugimoto K, Matsuda A et al.
Long-term responses and outcomes following immunosuppressive therapy in large
granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort
Study in Japan for the PRCA Collaborative Study Group. Haematologica 2008; 93:
1555–1559.
13 Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O et al. Analysis of a
French cohort of patients with large granular lymphocyte leukemia: a report on
229 cases. Haematologica 2010; 95: 1534–1541.
14 Lamy T, Loughran Jr TP. How I treat LGL leukemia. Blood 2011; 117: 2764–2774.
15 Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran Jr TP.
The lymphoproliferative disease of granular lymphocytes: updated criteria for
diagnosis. Blood 1997; 89: 256–260.
16 Morice WG, Kurtin PJ, Tefferi A, Hanson CA. Distinct bone marrow ﬁndings in T-
cell granular lymphocytic leukemia revealed by parafﬁn section immuno-
peroxidase stains for CD8, TIA-1, and granzyme B. Blood 2002; 99: 268–274.
17 Dhodapkar MV, Li CY, Lust JA, Tefferi A, Phyliky RL. Clinical spectrum of
clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of
undetermined signiﬁcance? Blood 1994; 84: 1620–1627.
18 Mohan SR, Clemente MJ, Afable M, Cazzolli HN, Bejanyan N, Wlodarski NW et al.
Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in
CD8þ large granular lymphocyte leukemia. Haematologica 2009; 94: 1407–1414.
19 Loughran Jr TP, Yao X, Bennett JM, Litzow MR, Evens AM, Tallman MS. Results of a
prospective multicenter phase ii study of initial treatment with methotrexate in LGL
leukemia (ECOG Protocol E5998). ASH Annual Meeting Abstracts 2010; 116: 702.
This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivs 3.0 Unported License. To view a copy of
this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
Inherited susceptibility to pre B-ALL caused by germline
transmission of PAX5 c.547G4A
Leukemia (2014) 28, 1136–1138; doi:10.1038/leu.2013.363
A single-nucleotide polymorphism (SNP) in PAX5 leading to an
amino-acid change in the octapeptide domain at position
c.547G4A (p.Gly183Ser) has recently been described to confer
an inherited susceptibility for childhood pre B-ALL.1 This
susceptibility was transmitted autosomal dominant in
two independent families with variable penetrance and
aberrations of chromosomal part 9p resulting in loss of the
wild-type (wt) PAX5 allele occurruring simultaneously in the
leukemic cells.
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